Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05587205 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Tolerability of EO2002

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 8, 2025 (before its estimated October 6, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 30, 2025 to Oct 6, 2026
    • Study completion date: Dec 1, 2025 to Oct 6, 2026
    • Study title shortened, about 3 words
    v5
  2. Primary completion date: Nov 30, 2023 to Jul 30, 2025
    • Study completion date: Jun 1, 2024 to Dec 1, 2025
    • Start date changed from estimate of Dec 1, 2022 to Aug 30, 2022
    v4
  3. Start date: Nov 1, 2022 to Dec 1, 2022v3
  4. Study title shortened, about 2 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.
Trial Details
NCT Number NCT05587205
Lead Sponsor Asociación para Evitar la Ceguera en México
Collaborators: Emmecell
Conditions
(from sponsor)		 Cataract, Endothelial Cell Loss, Corneal
Related terms Cataract, Corneal Endothelial Cell Loss
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov